• umbraco.MacroEngines.DynamicXml
    MED2002 Clinical Programme Update - Interview with James Barder

    Interview of James Barder, Chief Executive, by Proactive Investors in which he discusses the first Phase III efficacy trial for MED2002

  • umbraco.MacroEngines.DynamicXml
    Video Interview of James Barder discussing the Preliminary results for the year ended 31 December 2017

    Interview of James Barder, Chief Executive, by Proactive Investors in which he discusses the progress across Futura's portfolio of products.

  • umbraco.MacroEngines.DynamicXml
    MED2002 interview

    Interview of James Barder, Chief Executive, by Proactive Investors in which James discusses the recent article published by the Journal of Sexual Medicine.

  • umbraco.MacroEngines.DynamicXml
    MED2002 update

    Interview of James Barder, Chief Executive, by Proactive Investors in which James discusses the start of the PK study and provides a regulatory, clinical and commercial update.

  • umbraco.MacroEngines.DynamicXml
    Video Interview of James Barder discussing recent positive market research data on MED2002

    Interview of James Barder, Chief Executive, by Proactive Investors in which James discusses the positive market research data on MED2002 announced on 16 October 2017.

  • umbraco.MacroEngines.DynamicXml
    Video Interview of James Barder discussing the Interim results

    Interview of James Barder, Chief Executive, by Proactive Investors in which he discusses the Interim results for the period ending 30 June 2017 including the Phase III programme for MED2002 and the strategy for CSD500.

  • umbraco.MacroEngines.DynamicXml
    Video Interview of James Barder discussing Church and Dwight license termination

    Interview of James Barder, Chief Executive, by Proactive Investors in which he discusses the change of priorities which sees Futura Medical distributor terminate licensing agreement.

  • umbraco.MacroEngines.DynamicXml
    Video Interview of James Barder

    Video Interview of James Barder discussing a 'critical step' in the development of MED2002

  • umbraco.MacroEngines.DynamicXml
    Elevator Pitch

    CEO James Barder

  • umbraco.MacroEngines.DynamicXml
    Video Interview of James Barder

    Video Interview of James Barder discussing the Preliminary results for the year ended 31 December 2016

  • umbraco.MacroEngines.DynamicXml
    Video Interview of James Barder

    Video Interview of James Barder discussing the significant interest for MED2002, Futura’s erectile dysfunction gel based on Ipsos research

  • umbraco.MacroEngines.DynamicXml
    Video Interview of James Barder

    Video Interview of James Barder discussing the UK licensing agreement for its pain relief gel TPR100 and the launch of CSD500 in Saudi Arabia